A randomized, controlled, feasibility study of RD‐X19 in subjects with mild‐to‐moderate COVID‐19 in the outpatient setting

• Egile Nagusiak: Nathan Stasko (Egilea), Adam S. Cockrell (Egilea), Jacob F. Kocher (Egilea), Ibrahim Henson (Egilea), David Emerson (Egilea), Ye Wang (Egilea), Jonathan R. Smith (Egilea), Nathan H. Henderson (Egilea), Hillary Wood (Egilea), Shelton S. Bradrick (Egilea), Terry Jones (Egilea), Jorge Santander (Egilea), John G. McNeil (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2022-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract The RD‐X19 is an investigational, handheld medical device precisely engineered to emit blue light through the oral cavity to target the oropharynx and surrounding tissues. At doses shown to be noncytotoxic in an in vitro three‐dimensional human epithelial tissue model, the monochromatic vis...